PMID: 16640853Apr 28, 2006Paper

Neoadjuvant chemotherapy before radiotherapy in treatment of patients with cervical carcinoma

Zhonghua fu chan ke za zhi
Qing-shui LiQu-qing Song

Abstract

To study the value of neoadjuvant chemotherapy in treatment of cervical carcinoma. A clinical prospective study was carried out from Jan 1991 to Dec 2003. Totally 1609 patients with cervical carcinoma were given two cycles of combined chemotherapy before radiotherapy (neoadjuvant chemotherapy group, group A). Another 375 patients who accepted radiotherapy alone in our hospital from Jan 1989 to Dec 1990 were chosen as the control group (group B). Short-term control rate, long-term survival rate and complications were observed and analyzed. In group A, after two cycles of neoadjuvant chemotherapy, the overall response rate was 74.5% (1199/1609), the complete response rate was 1.6% (25/1609). The survival rate of 3, 5 and 10-year was 90.3% (1017/1126), 75.3% (652/866), and 59.0% (200/339), respectively. Five-year survival rate in stage II was higher than that in stage III (P < 0.05), but 3-year and 10-year survival rate were not different between stages II and III (P > 0.05). In group B, 3, 5 and 10-year survival rate was 81.1% (304/375), 59.2% (222/375), and 40.3% (151/375), respectively. The 5-year and 10-year survival rate was significantly higher in stage II than that in stage III (P < 0.05). The 5 and 10-year survival rate wa...Continue Reading

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Niraj N Mahajan
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Niraj N Mahajan
Contributions to Gynecology and Obstetrics
S MancusoG Scambia
© 2022 Meta ULC. All rights reserved